Rooted in China, to Become a World-Class Biopharmaceutical Enterprise
CDMO Bases
Desheng Biotech
A key internationally oriented biologics CDMO base in Northeast China, with a planned site area of 300,000 square meters
The production line complies with the regulatory requirements of China, the EU, the U.S., and other regions.
A domestically leading biologics platform providing one-stop services spanning early-stage research, process development, and commercial production of drug substances and drug products for macromolecular drugs.
The Phase I project achieves a production capacity of 75,000 liters
Provincial smart factory and provincial digital workshop
3SBio Guangdong
Focusing on CDMO services for biologics, cell, and gene therapies, with the production lines complying with regulatory requirements in China, the EU, and the U.S.; and passed an on-site U.S. FDA inspection in 2025
Capable of producing GMP-grade plasmids, mRNA, and mRNA-LNP injections, with dedicated B+A-grade production lines for CAR-T cells, NK cells, stem cells, exosomes, and other cell therapies
Equipped for large-scale LVV and AAV virus production, with lab-scale, pilot-scale, and commercial antibody production lines
Maximum annual capacity: 200 million vials/prefilled syringes
SIGO
Addresses diverse needs for monoclonal, bispecific, and multispecific antibodies
Proprietary culture media and chromatography resins;
More than 20 years of proven commercial production and operation experience with large-scale stainless steel bioreactors
Real-world product launch experience with multiple drugs, with a 100% IND application approval rate
Sirton, Italy
A sterile preparation manufacturing base with an 80-year history
Production line approved by the EU
Manufacturing of prefilled syringes, vials, ampoules, and other dosage forms
Clients including world-renowned companies such as Mylan and Sanofi Aventis
Maximum annual capacity: 18 million vials/prefilled syringes
CN
